VCYT
Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company\'s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company\'s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte\'s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California.
Veracyte, Inc. (VCYT) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Revisions (F).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | B- (3.0) | C (2.2) | B- (3.0) | C+ (2.6) | F (0.0) | C (2.2) |
| 2026-11-08 | B- (3.0) | C (2.4) | B- (3.0) | C (2.3) | F (0.0) | C- (2.1) |
| 2026-11-01 | C (2.5) | C- (2.1) | B- (3.0) | B+ (3.6) | C+ (2.7) | C+ (2.8) |
| 2026-10-25 | C+ (2.6) | C- (2.1) | B- (3.0) | B- (3.1) | C+ (2.6) | C+ (2.7) |
| 2026-10-18 | C+ (2.7) | C- (2.1) | B- (3.0) | C (2.5) | C+ (2.6) | C+ (2.6) |